This episode explores ADHD in older adults through late-diagnosis stories and discussion of whether ADHD worsens with age, how normal aging and hormonal transitions overlap with ADHD, how clinicians distinguish lifelong ADHD from new cognitive changes, and what the evidence does and does not show about treatment and associated risks.
Does ADHD Get Worse with Age? Persistent Symptoms and Smart Treatment in Older Adults
John Washbush told ADDitude he suspected ADHD in his early sixties, was diagnosed at 70, and took his first dose of Ritalin on his 72nd birthday. He described living 70 years “day-by-day in the dark, totally clueless” and said he got the same instructions and went through the same motions as everyone else but rarely got the same results. Zophia was 63 when she recognized herself in a TV host’s account of ADHD and later received a diagnosis after years of therapy and frustration.
Dr. David Goodman’s ADDitude Q&A says ADHD does not necessarily get worse with age, though the experience may worsen because of additive effects of aging or medical illness. ADHD impairment waxes and wanes with demands, circumstances, and environment. Aging brings cognitive changes that overlap with abilities ADHD affects, and perimenopause, polypharmacy, mild cognitive impairment, and other psychiatric conditions can contribute to cognitive difficulty.
The articles state it is never too late to treat ADHD with medication, and stimulants remain the treatment of choice for older adults; treatment can improve cognition, mood, self-confidence, and daily functioning. There are no controlled trials of ADHD medications for people over 65, and trials tend to exclude people on other medications or with other conditions. Stimulant prescriptions for people over 65 are therefore technically off label—outside the age range formally tested and approved—which is an evidence and regulatory gap, not proof of unsafe use.
Stimulants may raise heart rate and blood pressure, so clinicians should monitor heart conditions, narrow-angle glaucoma, circulation problems such as Raynaud’s syndrome, urologic and sexual function, and drug interactions. Cardiac illness is not an absolute contraindication. The Q&A says it depends on the condition: stimulants are relatively safe six months after a heart attack or stent surgery, but the patient should confer with their doctor or cardiologist; atrial fibrillation requires ensuring medication does not worsen the arrhythmia; and hypertension is best treated and controlled with home monitoring and conversation with the prescriber.
A November 2022 meta-analysis of 19 observational studies including 3.9 million participants found no statistically significant association between ADHD medications and cardiovascular disease, even among middle-aged and older adults. This is an association finding, not a guarantee for an individual. The Q&A notes there is no research to date on non-stimulants for adults over 65, and non-stimulants can also raise blood pressure and pulse in some people.
Side effects that matter more with age include dry mouth and dentures, urinary hesitancy in men with an enlarged prostate, appetite suppression and weight loss, and diabetes medication adjustments. Women whose ADHD symptoms are compounded by perimenopause may benefit from a dosage increase, and hormone replacement therapy may help mood and cognitive symptoms with the gynecologist and ADHD provider working together. Quinn’s estrogen-therapy discussion cautions that progesterone can negatively affect focus, that women should add progestin at regular intervals to protect against uterine cancer, and that postmenopausal women should consult their doctors, especially with a history of vascular problems or cancer.
A 2023 study followed more than 109,000 participants for 17 years and found that, compared with people without ADHD, people with ADHD had a 2.77 times greater risk for dementia after adjusting for factors such as obesity and diabetes. The article describes this as an association and says much more research is needed to understand the ADHD-dementia link. It also reported that participants treated with medication had less dementia risk than those unexposed and states that ADHD medication does not increase dementia risk; the conversation noted this cannot be turned into “stimulants prevent dementia.”
A 2023 Columbia-led study compared older adults with ADHD with same-age drivers and reported that adults aged 65 to 79 with ADHD were 74 percent more likely to have car crashes, 102 percent more likely to have traffic tickets, and 7 percent more likely to have hard-braking events. These are group-level associations about driving outcomes, not predictions about any one driver.
The article quotes Arnold, 73, asking whether diagnosis is worth it when he is “functioning OK.” It says the value depends on life circumstances, but diagnosis is necessary for medical treatment and insurance coverage of testing, medication, psychotherapy, and behavioral interventions, and age should never deter an evaluation. Late diagnosis can bring shock, confusion, sadness, guilt, relief, and regret, including “if only” thoughts; diagnosis can be a fresh start and can also bring grief. The article mentions talk therapy for low self-esteem and negative self-talk, cognitive behavioral therapy for practical ADHD behaviors, coaching, and general strategies such as intellectually stimulating activities, exercise, social connection, and supplements like fish oil and vitamin D, presented as general suggestions rather than a substitute for individualized care.
The Q&A notes ADHD in older adults is a very new area of clinical study and most clinicians have no training in it. Goodman suggests bringing research studies to an appointment and, if a doctor still will not consider stimulants because of age or existing conditions, seeking a second opinion from a clinician experienced in adult ADHD and verifying that experience before scheduling. Telehealth can help access, though interstate prescription rules may restrict the evaluator from prescribing; a comprehensive evaluation report might let someone local follow up with treatment.
Inside the Aging ADHD Brain
Normal cognitive aging includes declines in processing speed; executive function, including planning, organizing, and executing; working memory; selective attention, or shutting out distractions; episodic memory, or memory for events; response inhibition, such as holding back a blurt; divided attention, or multitasking; and driving skills. ADHD touches several of the same areas, so differentiating them is often difficult.
Estrogen is described as acting like a “sticky mitt” at the synapse, helping catch neurotransmitters. Dr. Patricia Quinn says lower estrogen lowers dopamine and norepinephrine and cognitive function, and that for women with ADHD lower estrogen means symptoms get worse—a biological fact, not imagination. Estradiol is one of three active estrogens and sensitizes neural receptors and supports connections between norepinephrine and dopamine, which are involved in alertness, focus, and motivation. Many women are diagnosed in their late thirties or forties during perimenopause, when estrogen becomes erratic and then increasingly absent; hormonal transition can be a revealer, not necessarily a creator.
For men, testosterone declines gradually, and lower levels influence sleep quality, mood swings, and cognitive decline. At Dr. Anthony Rostain’s clinic, twice as many men as women come seeking a possible ADHD diagnosis. The conversation noted this could reflect referral or help-seeking patterns and should not be overread from one clinic’s numbers.
Signs of Adult ADHD? Or Old Age?
The article argues there is no “adult onset” ADHD in the sense of a brand-new condition appearing in midlife; it starts at birth and continues. Lifelong symptoms can become more visible when compensation strategies stop working, such as during simultaneous care for aging parents and children, an empty nest, divorce, grief, or new health problems, and hormones can tip the balance.
Rostain’s line is that the salient feature is the difference between someone who never had ADHD symptoms but is now more forgetful and someone who has always been distracted. A good evaluation should take a lifelong history and distinguish lifelong distraction from new forgetfulness. Recent-onset problems could be a sign to test further for Alzheimer’s disease and other progressive cognitive decline. The article says there is no known connection between mild cognitive impairment, Alzheimer’s disease, and ADHD; overlap in symptoms does not mean one causes the other.
ADHD cannot be identified by a blood test or brain scan; behavioral markers from an in-depth intake interview are the gold standard. The DSM-5 requires six impairing symptoms for children and adolescents 17 and younger, but five for adults over 17. Some researchers suggest even fewer might be appropriate over 40, but that is a suggestion, not an established standard. Dr. William Dodson argues most symptom criteria and questionnaires were designed for children, and that to meet child-based criteria an adult would have to function at the level of an elementary-school-age child with untreated ADHD. The conversation framed this as a critique of the tools, not a reason to self-diagnose.
Podcast Transcript
Aaron: Welcome to Living on the Spectrum. I'm Aaron.
Jamie: And I'm Jamie.
Aaron: Today we're talking about ADHD in older adults, and I want to start with a specific story. A man named John Washbush told ADDitude he suspected ADHD in his early sixties, was diagnosed at seventy, and took his first dose of Ritalin on his seventy-second birthday. He described living seventy years "day-by-day in the dark, totally clueless." That's a strong phrase. What stands out to you?
Jamie: The late timing, and how ordinary the mismatch sounds. He said he got the same instructions and went through the same motions as everyone else but rarely got the same results. That's not a failure of effort. It describes a persistent, invisible difference in how tasks and demands land. The article also mentions Zophia, who was sixty-three when she recognized herself in a TV host's account of ADHD and later received a diagnosis after years of therapy and frustration. These are adults, and the question is what aging adds.
Aaron: Right. And the obvious listener question is: does ADHD get worse with age? The ADDitude Q&A with Dr. David Goodman says not necessarily. It says the experience of ADHD may worsen with age because of additive effects of aging or medical illness. Can you unpack that?
Jamie: Yes. ADHD impairment waxes and wanes depending on demands, circumstances, and environment. Aging brings its own cognitive changes—processing speed, time management, organization, task shifting—and those overlap with abilities ADHD already affects. So someone may feel worse without the underlying ADHD changing in some simple linear way. The Q&A also lists perimenopause, increasing polypharmacy—more medications—mild cognitive impairment, and other psychiatric conditions as contributors to cognitive difficulty with age.
Aaron: So it's not "ADHD is a progressive disease." It's more like the scaffolding gets more complicated.
Jamie: That's a fair everyday translation. And the companion ADDitude piece by Linda Roggli makes the overlap concrete. Normal cognitive aging includes declines in processing speed; executive function—planning, organizing, and executing; working memory; selective attention—shutting out distractions; episodic memory, or memory for events; response inhibition, like holding back a blurt; divided attention, or multitasking; and driving skills. ADHD touches several of the same areas. So differentiating them is often difficult.
Aaron: Which is why a lot of people in their forties, fifties, and beyond wonder if they're developing ADHD or just aging. The article says there's no "adult onset" ADHD. It starts at birth and continues. But menopause or life stress can unmask it?
Jamie: The article argues there's no adult-onset ADHD in the sense of a brand-new condition appearing in midlife. What can happen is that lifelong symptoms become more visible when compensation strategies stop working. The piece gives examples like caring for aging parents and children at the same time, an empty nest, divorce, grief, or new health problems. Hormones can tip the balance too.
Aaron: Let's talk about the hormone piece, because that's a big everyday question. The article describes estrogen as acting like a "sticky mitt" at the synapse, helping catch neurotransmitters. Dr. Patricia Quinn says lower estrogen lowers dopamine and norepinephrine and cognitive function. For women with ADHD, lower estrogen means symptoms get worse. She calls that a biological fact, not imagination.
Jamie: Yes. Estradiol is one of three active estrogens, and the article says it sensitizes neural receptors and supports connections between norepinephrine and dopamine, which are involved in alertness, focus, and motivation. Quinn reports many women are diagnosed in their late thirties or forties during perimenopause, when estrogen becomes erratic and then increasingly absent. That doesn't mean every midlife woman has ADHD. It means hormonal transition can be a revealer, not necessarily a creator.
Aaron: And for men, testosterone declines gradually. The article says lower levels influence sleep quality, mood swings, and cognitive decline. It also notes that at Dr. Anthony Rostain's clinic, twice as many men as women come seeking a possible ADHD diagnosis. That's interesting—maybe referral patterns, maybe who feels permitted to ask.
Jamie: Could be. We shouldn't overread one clinic's numbers. But it's a reminder that adult ADHD isn't a women's issue or a men's issue; presentation and help-seeking both vary.
Aaron: Okay, so someone listens and thinks, "This sounds like me. What does an evaluation even look like?" The article says ADHD can't be identified by a blood test or brain scan. Behavioral markers from an in-depth intake interview are the gold standard. It also notes the DSM-5 requires six impairing symptoms for children and adolescents seventeen and younger, but five for adults over seventeen. Some researchers suggest even fewer might be appropriate over forty, but that's a suggestion, not an established standard.
Jamie: Exactly. And Dr. William Dodson makes a sharp point: most symptom criteria and questionnaires were designed for children. He argues that to meet child-based criteria, an adult would have to function at the level of an elementary-school-age child with untreated ADHD. That's a critique of the tools, not a reason to self-diagnose. The practical takeaway is that a good evaluation should take a lifelong history and distinguish lifelong distraction from new forgetfulness.
Aaron: Rostain's line in the article is useful: the salient feature is the difference between someone who never had ADHD symptoms but is now more forgetful and someone who has always been distracted. That seems like a question a clinician would ask, not something a listener should use as a quiz.
Jamie: Right. And if problems are recent-onset, the article says that could be a sign to test further for Alzheimer's disease and other progressive cognitive decline. It also says there's no known connection between mild cognitive impairment, Alzheimer's disease, and ADHD. That's important: overlap in symptoms does not mean one causes the other.
Aaron: Let's get to treatment, because the articles are clear that it's never too late to treat ADHD with medication. But there's a real safety conversation in older adults. What does the evidence say?
Jamie: The articles say stimulants remain the treatment of choice for older adults, and the Q&A says treatment can improve cognition, mood, self-confidence, and daily functioning. But there are no controlled trials of ADHD medications for people over sixty-five. Trials tend to exclude people on other medications or with other medical conditions, so any stimulant prescription for someone over sixty-five is technically off label—meaning prescribed outside the age range the drug was formally tested and approved for. That's a regulatory and evidence-gap statement, not proof that it's unsafe.
Aaron: And cardiac risk is the thing many people worry about. The article says stimulants may raise heart rate and blood pressure, so doctors should monitor heart conditions, eye conditions such as narrow-angle glaucoma, circulation problems such as Raynaud's syndrome, urologic and sexual function, and drug interactions. It also says cardiac illness should not be an absolute contraindication. Can you walk through that?
Jamie: The Q&A says the short answer is yes, someone with a heart condition can take ADHD medication, but it depends on the nature of the condition. It says it's relatively safe to take stimulant medication six months after a heart attack and after stent surgery, but the patient should confer with their doctor or cardiologist. With atrial fibrillation—an irregular heart rhythm—it's critical to ensure medication doesn't worsen the arrhythmia. With hypertension, it's best if blood pressure is treated and controlled, with home monitoring and conversation with the prescriber.
Aaron: So "ask your cardiologist" isn't a brush-off. It's part of the actual protocol.
Jamie: Right. And there's reassuring observational evidence. A November 2022 meta-analysis of nineteen observational studies, including 3.9 million participants, found no statistically significant association between ADHD medications and cardiovascular disease, even among middle-aged and older adults. That's association, not a guarantee for an individual. The Q&A also notes there's no research to date on non-stimulants for adults over sixty-five, and non-stimulants can also raise blood pressure and pulse in some people.
Aaron: What about dosage changes? The article mentions side effects that matter more with age—dry mouth and dentures, urinary hesitancy in men with an enlarged prostate, appetite suppression and weight loss, diabetes medication adjustments. That's very practical.
Jamie: Very. It also mentions women whose ADHD symptoms are compounded by perimenopause may benefit from a dosage increase, and hormone replacement therapy may help mood and cognitive symptoms, with the gynecologist and ADHD provider working together. Quinn's specific estrogen-therapy discussion includes cautions: progesterone can negatively affect focus, but women should add progestin at regular intervals to protect against uterine cancer, and postmenopausal women should consult their doctors, especially with a history of vascular problems or cancer. That's firmly a conversation for a clinician.
Aaron: There's also a dementia finding that I want to handle carefully. A 2023 study followed more than 109,000 participants for seventeen years and found that, compared with people without ADHD, people with ADHD had a 2.77 times greater risk for dementia, even after adjusting for factors such as obesity and diabetes. But that's an association, right?
Jamie: Yes. The article says the study found an association and that much more research is needed to understand the ADHD-dementia link. It also compared stimulant use and found that participants treated with medication had less dementia risk than those unexposed. The article says ADHD medication does not increase dementia risk. But we can't turn that into "stimulants prevent dementia." That would be overreach.
Aaron: Good. Another practical finding: a 2023 Columbia-led study compared older adults with ADHD with a group of drivers the same age and reported that adults aged sixty-five to seventy-nine with ADHD were 74 percent more likely to have car crashes, 102 percent more likely to have traffic tickets, and 7 percent more likely to have hard-braking events. The article reports these as group-level associations about driving outcomes, not a prediction about any one driver.
Jamie: Exactly. And it's a reminder that "functioning okay" can coexist with risks that show up in group data. The article quotes someone named Arnold asking, "Is it even worth it at age 73, when I am functioning OK?" The article's answer is that the value of diagnosis depends on life circumstances, but diagnosis is necessary for medical treatment and insurance coverage of testing, medication, psychotherapy, and behavioral interventions. Age should never deter an evaluation.
Aaron: I like that it doesn't oversell diagnosis as a cure-all. The article also talks about late-diagnosis emotions—shock, confusion, sadness, guilt, relief, and regret. People think, "If only I'd known earlier, I could have started a business, finished college, learned to forgive my mistakes." Diagnosis can be a fresh start, but it can also bring grief.
Jamie: That's a real part of the clinical picture. The article mentions talk therapy for low self-esteem and negative self-talk, cognitive behavioral therapy for practical ADHD behaviors, and coaching to get and stay on track. It also lists general strategies that overlap with cognitive health: intellectually stimulating activities, exercise, social connection, and supplements like fish oil and vitamin D. Those are presented as general suggestions in the article, not a substitute for individualized care.
Aaron: There's also the clinician-training problem. The Q&A says ADHD in older adults is a very new area of clinical study and most clinicians have no training or understanding of it. Goodman says it's easier to educate the uninformed than the misinformed. He suggests bringing research studies to an appointment. If a doctor still won't consider stimulants because of age or existing conditions, he suggests a second opinion from a clinician experienced in adult ADHD—and verifying that experience before scheduling.
Jamie: And the article notes telehealth can help with access, though interstate prescription rules may restrict the evaluator from prescribing. A comprehensive evaluation report might let someone local follow up with treatment. The bigger point is that older adults deserve the same workup as anyone else at any age. That's Rostain's line, and it's a good standard.
Aaron: So if we're leaving listeners with something, it's not "check yourself." It's that if this sounds familiar, a proper evaluation can separate lifelong ADHD from new cognitive changes and from other conditions. And treatment decisions are individual, with benefits and risks weighed by the person and their clinicians.
Jamie: Right. The articles are careful that ADHD does not necessarily worsen with age, that medication safety in older adults requires monitoring, and that the dementia and cardiac findings are areas of evolving research, not simple certainties.
Aaron: Thanks for listening to Living on the Spectrum. Links to the original articles are on the episode page. Take care.
Jamie: Take care.